Results 251 to 260 of about 21,836 (300)

Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside

Antimicrobial Agents and Chemotherapy, 2019
Echinocandins (caspofungin, micafungin, anidulafungin), targeting β-1,3-glucan synthesis of the cell wall, represent one of the three currently available antifungal drug classes for the treatment of invasive fungal infections.
Frederic Lamoth
exaly   +2 more sources

Resistance of Candida to azoles and echinocandins worldwide

Clinical Microbiology and Infection, 2019
K. E. Pristov, M. Ghannoum
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary‐care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins

Mycoses (Berlin), 2021
Candida auris is an emerging, potentially multidrug‐resistant pathogen that exhibits clade‐specific resistance to fluconazole and also develops resistance to echinocandins and amphotericin B easily. This study analysed 49 C auris isolates for alterations
M. Asadzadeh, E. Mokaddas, Suhail Ahmad, A. Abdullah, Theun de Groot, J. Meis, Shama A Shetty   +6 more
semanticscholar   +1 more source

Echinocandins: production and applications

Applied Microbiology and Biotechnology, 2013
The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás Emri
exaly   +4 more sources

Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta‐analysis

Mycoses (Berlin), 2021
The echinocandins, amphotericin B preparations, voriconazole and fluconazole are approved for the treatment of invasive candidiasis, though it remains unclear which agent is most effective.
Koray K Demir, G. Butler-Laporte, O. Del Corpo, T. Ekmekjian, D. Sheppard, T. Lee, M. Cheng   +6 more
semanticscholar   +1 more source

Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS

Frontiers in Cellular and Infection Microbiology, 2019
Candida auris was first reported in an ear swab from Japan in 2009; it then promptly spread over five continents and turned into a global nosocomial problem. The main challenges faced by many researchers are the mis-identification by conventional methods
Teunis Boekhout, Jacques F Meis, Judith G Berman   +2 more
exaly   +2 more sources

Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents.

Journal of the Pediatric Infectious Diseases Society, 2021
BACKGROUND Invasive candidiasis is the most common invasive fungal disease in children and adolescents, but there are limited pediatric-specific antifungal effectiveness data.
B. Fisher, T. Zaoutis, R. Xiao, Rachel L. Wattier, E. Castagnola, Z. Pana, Allison Fullenkamp, Craig L K Boge, Rachael K. Ross, I. Yildirim, D. Palazzi, L. Danziger-Isakov, Surabhi B. Vora, A. Arrieta, Dwight E. Yin, M. Avilés-Robles, Tanvi S. Sharma, A. Tribble, Gabriela M. Maron, D. Berman, Michael D. Green, L. Sung, J. Romero, S. Hauger, E. Roilides, K. Belani, D. Nolt, P. Soler-Palacín, Eduardo López-Medina, W. Muller, Natasha B Halasa, D. Dulek, Ibrahim Hussain, Alice Pong, J. Hoffman, S. Rajan, B. E. Gonzalez, B. Hanisch, Catherine Aftandilian, F. Carlesse, M. Abzug, A. Huppler, C. Salvatore, M. Ardura, A. Chakrabarti, M. Santolaya, A. Localio, W. Steinbach   +47 more
semanticscholar   +1 more source

The Echinocandins

Pharmacotherapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty, Kasi, Eiselstein-McKitrick   +1 more
exaly   +3 more sources

Echinocandins in Children

Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Thomas J. Walsh, Jill A. Hoffman
openaire   +2 more sources

Micafungin - The newest echinocandin

Drugs of Today, 2009
Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem Temesgen, Sandro Vento, Jason N. Barreto   +2 more
openaire   +3 more sources